Literature DB >> 2141612

Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison.

J Julien1, M A Dufloux, R Prasquier, G Chatellier, D Menard, P F Plouin, J Menard, P Corvol.   

Abstract

In a double-blind 6 month trial, the cardiac effects of captopril and minoxidil, administered as third step treatments, were compared in 34 men with essential hypertension and diastolic blood pressure greater than 95 mm Hg who were taking 200 mg/day of metoprolol and 80 mg/day of furosemide. Average daily doses of captopril and minoxidil were 269 mg (range 150 to 300) and 20 mg (range 7.5 to 30), respectively. At the end of the 6 months' treatment, blood pressure had dropped significantly in both groups, but echocardiographic criteria of hypertrophy improved only in the captopril group (intragroup comparison): blood pressure, thickness of the intraventricular septum and posterior wall, and the left ventricular mass index, respectively, decreased from 163/102 to 135/89 mm Hg (p less than 0.001), 17.4 to 15.9 mm (p less than 0.05), 14.5 to 13.4 mm (p less than 0.05) and 236 to 198 g/m2 (p less than 0.001). In the minoxidil group, blood pressure dropped from 160/99 to 137/87 mm Hg (p less than 0.001), but echocardiographic criteria were not significantly modified. Fractional shortening remained normal in both groups. These results show that in patients with severe left ventricular hypertrophy, captopril-based triple therapy reduces left ventricular mass without altering systolic performance, whereas minoxidil-based therapy does not.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141612     DOI: 10.1016/0735-1097(90)90470-a

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

Review 1.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 2.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 3.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Hypertension and left ventricular hypertrophy.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-08

Review 5.  Role of ACE inhibitors in hypertension with left ventricular hypertrophy.

Authors:  A M Richards; M G Nicholls; I G Crozier
Journal:  Br Heart J       Date:  1994-09

6.  An updated concept for left ventricular hypertrophy risk in hypertension.

Authors:  Edward D Frohlich
Journal:  Ochsner J       Date:  2009

Review 7.  Antihypertensive Therapies and Left Ventricular Hypertrophy.

Authors:  Elsayed Z Soliman; Ronald J Prineas
Journal:  Curr Hypertens Rep       Date:  2017-09-19       Impact factor: 5.369

8.  The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition.

Authors:  L M Pereira; C A Mandarim-De-Lacerda
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

Review 9.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 10.  Effects of exercise, diet and weight loss on high blood pressure.

Authors:  Simon L Bacon; Andrew Sherwood; Alan Hinderliter; James A Blumenthal
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.